Publications by the researcher in collaboration with Cezmi A. Akdis (25)

2023

  1. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 11, pp. 2851-2874

  2. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  3. Tonsillar transcriptional profiles in atopic and non-atopic subjects

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 2, pp. 522-536

  4. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs

    Nature Reviews Drug Discovery, Vol. 22, Núm. 9, pp. 743-767

2022

  1. Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 8, pp. 2337-2354

2021

  1. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy

    Clinical and Translational Allergy, Vol. 11, Núm. 4

  2. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  3. EAACI Biologicals Guidelines—dupilumab for children and adults with moderate-to-severe atopic dermatitis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 988-1009

  4. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 8, pp. 2337-2353

  5. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  6. Persistent human bocavirus 1 infection and tonsillar immune responses

    Clinical and Translational Allergy, Vol. 11, Núm. 6

  7. The cannabinoid WIN55212-2 restores rhinovirus-induced epithelial barrier disruption

    Allergy: European Journal of Allergy and Clinical Immunology

  8. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 6, pp. 1640-1660

2020

  1. A compendium answering 150 questions on COVID-19 and SARS-CoV-2

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2503-2541

  2. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  3. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  4. EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network

    Allergy: European Journal of Allergy and Clinical Immunology

  5. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

  6. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI)

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 10, pp. 2445-2476

  7. Type 2 immunity in the skin and lungs

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 7, pp. 1582-1605